Crossject Société Anonyme
Market Cap
€27.3m
Last Updated
2019/09/14 22:17 UTC
Data Sources
Company Financials +
Executive Summary
Crossject Société Anonyme develops needle-free injection systems.
Snowflake
Fundamentals
Worrying balance sheet with weak fundamentals.
Risks
- Crossject Société Anonyme has significant price volatility in the past 3 months.
- Crossject Société Anonyme is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Crossject Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-7.5%
ENXTPA:ALCJ
0.2%
FR Medical Equipment
0.6%
FR Market
1 Year Return
-53.1%
ENXTPA:ALCJ
-14.8%
FR Medical Equipment
4.2%
FR Market
ALCJ underperformed the Medical Equipment industry which returned -14.8% over the past year.
ALCJ underperformed the Market in France which returned 4.1% over the past year.
Share holder returns
| ALCJ | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.5% | 0.2% | 0.6% |
| 30 Day | -9.9% | -2.8% | 7.3% |
| 90 Day | -31.0% | -6.1% | 4.4% |
| 1 Year | -51.6%-53.1% | -13.9%-14.8% | 7.7%4.2% |
| 3 Year | -81.7%-82.6% | 23.7%21.1% | 48.9%34.5% |
| 5 Year | -85.0%-85.7% | 68.2%62.6% | 59.0%35.7% |
Price Volatility Vs. Market
How volatile is Crossject Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Investors Who Bought Crossject Société Anonyme (EPA:ALCJ) Shares Five Years Ago Are Now Down 82%4 months ago | Simply Wall St
How Crossject Société Anonyme (EPA:ALCJ) Can Impact Your Portfolio Volatility11 months ago | Simply Wall St
Is Crossject Société Anonyme (EPA:ALCJ) A Financially Sound Company?Valuation
Is Crossject Société Anonyme undervalued based on future cash flows and its price relative to the stock market?
11.15x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Crossject Société Anonyme to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Crossject Société Anonyme to establish if it is available at substantial discount.
Price Based on Earnings
Crossject Société Anonyme is loss making, we can't compare its value to the Europe Medical Equipment industry average.
Crossject Société Anonyme is loss making, we can't compare the value of its earnings to the France market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Crossject Société Anonyme, we can't assess if its growth is good value.
Price Based on Value of Assets
Crossject Société Anonyme is overvalued based on assets compared to the FR Medical Equipment industry average.
Next Steps
Future Growth
How is Crossject Société Anonyme expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
13.6%
Forecasted Healthcare industry annual growth in earnings
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Unable to determine if Crossject Société Anonyme is high growth as no revenue estimate data is available.
Crossject Société Anonyme is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to compare Crossject Société Anonyme's revenue growth to the France market average as no estimate data is available.
Unable to compare Crossject Société Anonyme's earnings growth to the France market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Crossject Société Anonyme's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Crossject Société Anonyme will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Crossject Société Anonyme performed over the past 5 years?
-23.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Crossject Société Anonyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Crossject Société Anonyme's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Crossject Société Anonyme's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Crossject Société Anonyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Crossject Société Anonyme has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Crossject Société Anonyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Crossject Société Anonyme's financial position?
Financial Position Analysis
Crossject Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Crossject Société Anonyme's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Crossject Société Anonyme's level of debt (391.4%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (130.5% vs 391.4% today).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1.3x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Crossject Société Anonyme has less than a year of cash runway based on current free cash flow.
Crossject Société Anonyme has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.7% each year.
Next Steps
Dividend
What is Crossject Société Anonyme's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Crossject Société Anonyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Crossject Société Anonyme's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Crossject Société Anonyme has not reported any payouts.
Unable to verify if Crossject Société Anonyme's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Crossject Société Anonyme has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Crossject Société Anonyme's dividends in 3 years as they are not expected to pay a notable one for France.
Next Steps
Management
What is the CEO of Crossject Société Anonyme's salary, the management and board of directors tenure and is there insider trading?
CEO
Patrick Alexandre 0
0yrs
Tenure
Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office ...
CEO Compensation Analysis
Patrick's remuneration is lower than average for companies of similar size in France.
Patrick's compensation has been consistent with company performance over the past year, both up more than 20%.
Insider Trading
No 3 month open market individual insider trading information.
Management Team
Patrick Alexandre
Co-Founder
- Tenure: 0yrs
Isabelle Liebschütz
Chief Quality & Regulatory Officer and Member of Executive Board
- Tenure: 0yrs
Henri de Parseval
COO of Engineering & Industry and Member of Executive Board
- Tenure: 0yrs
Olivier Giré
COO of Specialty Pharma & Member of Executive Board
- Tenure: 0yrs
Board Members
Philippe Monnot
Chairman of Supervisory Board
- Tenure: 0yrs
Patrice Coissac (70yo)
Member of Supervisory Board
- Tenure: 0yrs
Jean-Francois Loumeau
Member of Supervisory Board
- Tenure: 1yrs
Company Information
Crossject Société Anonyme's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Crossject Société Anonyme
- Ticker: ALCJ
- Exchange: ENXTPA
- Founded: 1997
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €27.297m
- Shares outstanding: 20.07m
- Website: https://www.crossject.com
Number of Employees
Location
- Crossject Société Anonyme
- 6 Rue Pauline Kergomard
- Dijon
- Burgundy
- 21000
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ALCJ | ENXTPA (Euronext Paris) | Yes | Common Stock | FR | EUR | Feb 2014 |
| 74C | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/14 22:17 |
| End of Day Share Price | 2019/09/13 00:00 |
| Earnings | 2018/12/31 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.